E7777 + CHOP

E7777 + CHOP is a combination regimen consisting of **E7777 (improved purity denileukin diftitox, a recombinant fusion protein)** and **CHOP chemotherapy** (cyclophosphamide, doxorubicin, vincristine, and prednisolone/prednisone). E7777 targets cells expressing the interleukin-2 receptor (CD25) by fusing diphtheria toxin fragments with human interleukin-2, leading to selective cytotoxicity via receptor-mediated internalization and inhibition of protein synthesis. CHOP is a well-known multi-agent chemotherapy that includes an alkylating agent (cyclophosphamide), an anthracycline (doxorubicin), a vinca alkaloid (vincristine), and a corticosteroid (prednisolone or prednisone), all of which have cytotoxic effects on rapidly dividing lymphoma cells. The primary indications for E7777 are cutaneous T-cell lymphoma (including persistent and recurrent forms)[5], while CHOP is primarily used in lymphomas, notably peripheral T-cell lymphoma and diffusive large B-cell lymphoma. E7777 is developed and manufactured by Citius Pharmaceuticals (following acquisition from Eisai), and CHOP drugs are generic and manufactured by various pharmaceutical companies.

Brand names

ONTAK

Other names

denileukin diftitoximproved purity ONTAKE7777E-7777E 7777CHOP